Shares of Doximity, Inc. (NASDAQ:DOCS – Get Free Report) have received a consensus recommendation of “Hold” from the twenty analysts that are covering the stock, MarketBeat.com reports. Thirteen equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $53.12.
A number of analysts recently commented on DOCS shares. Raymond James restated an “outperform” rating and set a $65.00 price target (up from $37.00) on shares of Doximity in a research note on Friday, November 8th. JPMorgan Chase & Co. increased their target price on Doximity from $30.00 to $48.00 and gave the stock a “neutral” rating in a research report on Thursday, November 21st. Canaccord Genuity Group lowered Doximity from a “buy” rating to a “hold” rating and raised their price target for the stock from $40.00 to $60.00 in a report on Wednesday, November 13th. Stephens assumed coverage on Doximity in a research note on Friday, December 20th. They set an “equal weight” rating and a $55.00 price objective on the stock. Finally, Mizuho assumed coverage on Doximity in a report on Wednesday, December 4th. They set a “neutral” rating and a $55.00 price objective on the stock.
Check Out Our Latest Report on Doximity
Institutional Investors Weigh In On Doximity
Doximity Stock Up 1.1 %
NASDAQ DOCS opened at $53.78 on Tuesday. The company has a market cap of $10.04 billion, a PE ratio of 61.82, a price-to-earnings-growth ratio of 4.12 and a beta of 1.38. Doximity has a 52 week low of $22.96 and a 52 week high of $61.75. The firm’s 50-day simple moving average is $53.57 and its two-hundred day simple moving average is $42.85.
About Doximity
Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.
Further Reading
- Five stocks we like better than Doximity
- What is the MACD Indicator and How to Use it in Your Trading
- 3 Stocks to Gain From Donald Trump’s External Revenue Service
- P/E Ratio Calculation: How to Assess Stocks
- AMD: Loop Capital’s Buy Rating Reinforces Investor Confidence
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Momentum Is Building for Qualcomm to Have a Strong Run in 2025
Receive News & Ratings for Doximity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Doximity and related companies with MarketBeat.com's FREE daily email newsletter.